ESMO 2026 | KEYNOTE-C93: pembrolizumab vs chemotherapy in dMMR endometrial cancer
Brian Slomovitz, MD, Mount Sinai Comprehensive Cancer Center, Miami, FL, discusses results from the Phase III KEYNOTE-C93/GOG-3064/ENGOT-en15 study (NCT05173987), which compared first-line pembrolizumab with carboplatin plus paclitaxel in mismatch repair-deficient (dMMR) advanced or recurrent endometrial carcinoma. Pembrolizumab significantly improved progression-free survival, with a favorable overall survival trend, better quality of life and fewer severe treatment-related adverse events. No new safety signals emerged, supporting single-agent pembrolizumab as a chemotherapy-free option for this population. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
